• Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway 

      Rahman, Mohummad Aminur; Engelsen, Agnete; Sarowar, Shahin; Bindesbøll, Christian; Birkeland, Even; Goplen, Dorota; Lotsberg, Maria Lie; Knappskog, Stian; Simonsen, Anne Gjøen; Enger, Martha (Journal article; Peer reviewed, 2022)
      Introduction: Glioblastoma (GBM) is invariably resistant to temozolomide (TMZ) chemotherapy. Inhibiting the proteasomal pathway is an emerging strategy to accumulate damaged proteins and inhibit their lysosomal degradation. ...
    • Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival 

      Rahman, Mohummad Aminur; Gras Navarro, Andrea; Brekke, Jorunn; Engelsen, Agnete; Bindesbøll, Christian; Sarowar, Shahin; Bahador, Marzieh; Bifulco, Ersilia; Goplen, Dorota; Waha, Andreas; Lie, Stein Atle; Gjertsen, Bjørn Tore; Selheim, Frode; Enger, Per Øyvind; Simonsen, Anne; Enger, Martha Chekenya (Peer reviewed; Journal article, 2019-08-15)
      Background Resistance to temozolomide (TMZ) is due in part to enhanced DNA repair mediated by high expression of O6-methyl guanine DNA methyltransferase (MGMT) that is often characterised by unmethylated promoter. Here, ...